Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $14.69, but opened at $13.93. Astellas Pharma shares last traded at $14.26, with a volume of 37,675 shares trading hands.

Analyst Ratings Changes

Separately, Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Astellas Pharma presently has an average rating of “Moderate Buy”.

Astellas Pharma Stock Down 1.4%

The stock’s fifty day moving average price is $14.15 and its 200 day moving average price is $14.59. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The stock has a market cap of $25.75 billion, a P/E ratio of 10.83 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.